Kyoto University

Other

Panasonic Corporation

Ono Pharmaceutical Co., Ltd.

Eisai R&d Management Co., Ltd.

Osaka University

The Salk Institute for Biological Studies

Tokyo Institute of Technology

Sumitomo Dainippon Pharma Co., Ltd.

Sumitomo Pharma Co., Ltd.

Ono Pharmaceuticals Co., Ltd.

Racthera Co., Ltd.

Honjo, Tasuku

Jun Takahashi

Daisuke Doi

Motoji Ohmori

Toshihisa Nakano

Kaoru Yokota

Shunji Harada

Tasuku Honjo

Yoshikatsu Ito

Kei Tashiro

Hiroki Toda

Masaya Miyazaki

Yuichi Ono

Masayo Takahashi

Atsushi Kuwahara

Bumpei Samata

Asuka Morizane

Kenji Yoshida

Takashi Takahashi

Fred Harrison Gage

Hachiro Sugimoto

Kiyotoshi Sekiguchi

Ichiro Hijikuro

Theo Palmer

Makoto Motono

Francis G Safar

Yoshihiko Ioroi

A cell population comprising Corin- and/or Lrtm1-positive cells was produced by the following steps (1) and (2), from which Corin positive and/or Lrtm1 positive cells are collected using a substance that binds to Corin and/or a substance that binds to Lrtm1, and dopaminergic neuron progenitor cells are produced by performing suspension culture of the Corin positive and/or Lrtm1 positive cells in a culture solution containing one or more nutritional factors:

Method for producing dopaminergic neuron progenitor cell

The present invention provides a method for producing dopaminergic neuron progenitor cells from pluripotent stem cells, which method comprises the steps of: (i) performing adherent culture of pluripotent stem cells on an extracellular matrix in a medium containing a reagent(s) selected from the group consisting of BMP inhibitor, TGF&#x3b2; inhibitor, SHH signal-stimulating agent, FGF8, and GSK3&#x3b2; inhibitor; (ii) collecting Corin- and/or Lrtm1-positive cells from the cells obtained in Step (i) using a substance which binds to Corin and/or a substance which binds to Lrtm1; and (iii) performing suspension culture of the cells obtained in Step (ii) in a medium containing a neurotrophic factor.

Method for inducing dopaminergic neuron progenitor cells

The present invention provides a method for inducing differentiation of pluripotent stem cells into neural precursor cells, comprising culturing the pluripotent stem cells in the presence of a small, molecule BMP inhibitor, and induced neural precursor cells prepared by this method.

Method for inducing differentiation of pluripotent stem cells into neural precursor cells

Provided is a method for producing cerebral cortex neurons from pluripotent stem cells. Provided is a method for producing cerebral cortex neurons from pluripotent stem cells, comprising (i) a step of performing a suspension culture of pluripotent stem cells in a culture medium containing a TGF&#x3b2; inhibitor, bFGF, a Wnt inhibitor, and a BMP inhibitor, (ii) a step of performing a suspension culture of the cells obtained in the step (i) in a culture medium containing a Wnt inhibitor and a BMP inhibitor, and (iii) a step of further culturing the cells obtained in the step (ii).

Method for inducing cerebral cortex neurons

The present invention provides a method for inducing differentiation of pluripotent stem cells into neural precursor cells, comprising culturing the pluripotent stem cells in the presence of a small molecule BMP inhibitor, and induced neural precursor cells prepared by this method.

The present invention provides a transplantation adjuvant for neural progenitor cells containing valproic acid and/or zonisamide as an active ingredient.

Transplantation adjuvant in cell therapy using neural progenitor cells

The present invention provides a method for selecting dopaminergic neuron progenitor cells, which comprises detecting any one or more of markers selected from the group consisting of CD15 (SSEA-1), CD24, CD46, CD47, CD49b, CD57, CD58, CD59, CD81, CD90, CD98, CD147, CD184, Disalogangliosid GD2, SSEA-4, CD49f, SERINC4, CCR9, PHEX, TMPRSS11E, HTR1E, SLC25A2, Ctxn3, Ccl7, Chrnb4, Chrna3, Kcnv2, Grm2, Syt2, Lim2, Mboat1, St3gal6, Slc39a12, Tacr1, Lrtm1, Dscam and CD201.

Markers for dopaminergic neuron progenitor cells

The present invention provides a novel indoline derivative or a pharmacologically acceptable salt thereof or a solvate of the derivative or a salt thereof represented by the following formula (1) that has an excellent butyrylcholinesterase inhibitory activity. In the formula, Rrepresents an alkyl group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, a heteroaryl group, an arylalkyl group, a heteroarylalkyl group, a cycloalkylalkyl group, a heterocycloalkylalkyl group, a dihydrofurylalkyl group, an alkenyl group, a tetrahydronaphthyl group, or an indanyl group; Rrepresents a hydrogen atom, an alkyl group, an arylalkyl group, a cycloalkylalkyl group, a heteroarylalkyl group, a heterocycloalkylalkyl group, an aryl group, or an acyl group; Reach independently represents a hydrogen atom, an alkyl group, or a dialkylaminocarbonyl group; Reach independently represents a hydrogen atom or an alkyl group; and Rrepresents a hydrogen atom or an alkyl group. Each functional group may have a substituent. 

Indoline derivatives

A recording/playback apparatus is capable of using pre-image-converted content in a case of transferring an image-converted content to another device, then back from transfer-destination device to the recording/playback apparatus. The recording/playback apparatus includes a storage unit that stores a first encrypted content generated by encrypting the content, a second encrypted content generated by performing an irreversible compression to convert the content, thereby obtaining a converted content, and by encrypting the converted content, and a content key for decryption of the first and second encrypted contents, a key transfer unit that writes the content key to the external recording medium, and erases the content key stored in the storage unit, and a content transfer unit that, after the content key has been erased, writes the second encrypted content to the external recording medium, and erases the second encrypted content from the storage unit.

Recording device, recording medium, and content protection system

The recorder/reproducer, when moving a first content data, writes a second content data, which is obtained by re-coding the first content data recorded in a first recording medium, into a second recording medium instead of the first content data, writes one or more first partial information extracted from the first content data into the second recording medium, and makes the first content data irreproducible, using one or more first invalidated partial information having one-to-one correspondence with the extracted one or more first partial information. When restoring the first content data, it makes the irreproducible first content data reproducible, using the one or more first partial information recorded in the second recording medium.

Recorder/reproducer and content data protection system for preventing unauthorized use of content

The present invention relates to human, rat and mouse stem cell-derived neuron survival factor polypeptides (SDNSF), a process for producing them, cDNA encoding SDNSF, a vector comprising the cDNA, host cells transformed by the vector, an antibody against SDNSF, pharmaceutical compositions containing SDNSF or the antibody, a method of assaying SDNSF, a reagent for assaying SDNSF, and a screening method using SDNSF. The polypeptides are effective in the survival of nerve cells and, therefore, efficacious in treating injury to the central nerve system caused by brain infarction, brain hemorrhage, spinal cord injury, etc.

Human and mammalian stem cell-derived neuron survival factors

The present invention relates to human, rat and mouse stem cell-derived neuron survival factor polypeptides (SDNSF), a process for producing them, cDNA encoding SDNSF, a vector comprising the cDNA, host cells transformed by the vector, an antibody against SDNSF, pharmaceutical compositions containing SDNSF or the antibody, a method of assaying SDNSF, a reagent for assaying SDNSF, and a screening method using SDNSF. The polypeptides are effective in the survival of nerve cells and neuronal stem cells, therefore, efficacious in treating injury to the central nerve system and cancer.

To provide a highly user-friendly content moving device which prevents unauthorized copying of content and, when content that has been irreversibly converted and moved to a recording medium is moved back to a move source, can use the content in its form before irreversible conversion. A partial information extraction unit extracts, from content stored on a content storage unit, partial data necessary for playback of the content, and a write/read unit writes the partial data to a partial information storage unit and overwrites a portion of the content corresponding to the partial data with different data, while a conversion unit transcodes the content and writes the transcoded content and the partial data to the recording medium.

Growing community of inventors

Kyoto, Japan

Jun Takahashi